Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Glaucoma-Pipeline Review, H1 2015

Glaucoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Glaucoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Glaucoma-Pipeline Review, H1 2015', provides an overview of the Glaucoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Glaucoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Glaucoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Glaucoma Overview 11

Therapeutics Development 12

Pipeline Products for Glaucoma-Overview 12

Pipeline Products for Glaucoma-Comparative Analysis 13

Glaucoma-Therapeutics under Development by Companies 14

Glaucoma-Therapeutics under Investigation by Universities/Institutes 18

Glaucoma-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Glaucoma-Products under Development by Companies 23

Glaucoma-Products under Investigation by Universities/Institutes 29

Glaucoma-Companies Involved in Therapeutics Development 30

AC Immune SA 30

Acadia Pharmaceuticals Inc. 31

Aerie Pharmaceuticals, Inc. 32

Alcon, Inc. 33

Allergan, Inc. 34

Altacor Ltd. 35

Amakem NV 36

Asahi Kasei Pharma Corp. 37

AUS Bio Limited 38

Bausch & Lomb Incorporated 39

Bionure Farma, S.L. 40

Can-Fite BioPharma Ltd. 41

Cellular Biomedicine Group, Inc. 42

China Grand Wuhan General Pharmaceutical Research Institute 43

D. Western Therapeutics Institute, Inc. 44

DNAVEC Corporation 45

Dompe Farmaceutici S.p.A. 46

F. Hoffmann-La Roche Ltd. 47

Foamix Pharmaceuticals Ltd. 48

Gene Signal International SA 49

Gilead Sciences, Inc. 50

Handok Inc. 51

High Point Pharmaceuticals, LLC 52

Icon Bioscience, Inc. 53

IMMD Inc. 54

Inotek Pharmaceuticals Corporation 55

InSite Vision Incorporated 56

Lacer, S.A. 57

Merck & Co., Inc. 58

Merz Pharma GmbH & Co. KgaA 59

Mimetogen Pharmaceuticals Inc. 60

NeoStem, Inc. 61

Neurotech Pharmaceuticals, Inc. 62

NicOx S.A. 63

Ocata Therapeutics, Inc. 64

Ocular Therapeutix, Inc. 65

Ohr Pharmaceutical Inc. 66

Ono Pharmaceutical Co., Ltd. 67

Otsuka Holdings Co., Ltd. 68

Oxford BioMedica plc 69

PharmaNova Inc. 70

Quark Pharmaceuticals, Inc. 71

Santen Pharmaceutical Co., Ltd. 72

Senju Pharmaceutical Co., Ltd. 73

SIFI S.p.A 74

SK Biopharmaceuticals Co., Ltd. 75

Sun Pharma Advanced Research Company Ltd. 76

Sylentis S.A. 77

Teva Pharmaceutical Industries Limited 78

Upsher-Smith Laboratories, Inc. 79

Glaucoma-Therapeutics Assessment 80

Assessment by Monotherapy Products 80

Assessment by Combination Products 81

Assessment by Target 82

Assessment by Mechanism of Action 86

Assessment by Route of Administration 90

Assessment by Molecule Type 92

Drug Profiles 94

(AR-13324 + latanoprost)-Drug Profile 94

(bimatoprost + brimonidine tartrate)-Drug Profile 95

(carteolol hydrochloride + latanoprost)-Drug Profile 96

(dorzolamide hydrochloride + latanoprost)-Drug Profile 97

(latanoprost + trabodenoson)-Drug Profile 98

(Prostaglandin Agonist + Beta-Blocker)-Drug Profile 99

(tafluprost + timolol maleate)-Drug Profile 100

AC-262271-Drug Profile 101

ACI-260-Drug Profile 102

ACN-1052-Drug Profile 103

aganirsen-Drug Profile 104

ALT-022-Drug Profile 106

AMA-0076-Drug Profile 107

Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy-Drug Profile 108

AP-022-Drug Profile 109

APH-1104-Drug Profile 110

AR-13324-Drug Profile 111

AR-13533-Drug Profile 112

ATS-8535-Drug Profile 113

BA-1049-Drug Profile 114

BA-240-Drug Profile 115

bimatoprost-Drug Profile 116

bimatoprost SR-Drug Profile 117

BN-201-Drug Profile 118

CF-101-Drug Profile 119

CNS-102-Drug Profile 122

DE-117-Drug Profile 123

dorzolamide hydrochloride nanoparticle-Drug Profile 124

Drugs for Steroid Induced Glaucoma-Drug Profile 125

Drugs to Inhibit Cadherin-5 for Glaucoma-Drug Profile 126

Drugs to Target Bestrophin-2 for Glaucoma-Drug Profile 127

ENV-515-Drug Profile 128

GB-201-Drug Profile 129

GB-202-Drug Profile 130

GB-203-Drug Profile 131

GB-204-Drug Profile 132

Gene Therapy for Glaucoma and Retinitis Pigmentosa-Drug Profile 133

Gene Therapy for Ocular Diseases-Drug Profile 134

Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension-Drug Profile 135

Glaucoma-GT-Drug Profile 136

GS-607601-Drug Profile 137

H-1129-Drug Profile 138

H-1129 Backup-Drug Profile 139

HL-5521-Drug Profile 140

HPP-851-Drug Profile 141

IMD-1041-Drug Profile 142

KR-12-Drug Profile 143

LA-8045-Drug Profile 144

latanoprost-Drug Profile 145

latanoprost-Drug Profile 146

latanoprost-Drug Profile 148

latanoprost-Drug Profile 149

latanoprost SR-Drug Profile 150

latanoprostene bunod-Drug Profile 152

lomerizine-Drug Profile 154

Lycium Anti-Angiogenic Proteoglycan-Drug Profile 155

MD-920G-Drug Profile 156

MIMD-3-Drug Profile 157

minocycline Gel-Drug Profile 158

Monoclonal Antibody to Activate Bves for Glaucoma-Drug Profile 159

MRZ-99030-Drug Profile 160

NB-1111-Drug Profile 161

NCX-1021-Drug Profile 162

NCX-250-Drug Profile 163

Neurovitas-Drug Profile 164

NT-501-Drug Profile 165

NT-509-Drug Profile 167

ONO-9054-Drug Profile 168

OPA-6566-Drug Profile 169

PBF-695-Drug Profile 170

PRX-00933-Drug Profile 171

QPI-1007-Drug Profile 172

R-807-Drug Profile 173

Recombinant Human Nerve Growth Factor-Drug Profile 174

RO-5093151-Drug Profile 175

SF-103-Drug Profile 177

SF-108-Drug Profile 178

SF-109-Drug Profile 179

SF-116-Drug Profile 180

SKL-G-Drug Profile 181

SKS-1002-Drug Profile 182

Small Molecule for Glaucoma-Drug Profile 183

Small Molecule for Glaucoma-Drug Profile 184

Small Molecule to Inhibit Rho Kinase for Glaucoma-Drug Profile 185

Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy-Drug Profile 186

Small Molecules for CNS Disorders and Ophthalmology-Drug Profile 187

Small Molecules to Activate sGC for Ophthalmology-Drug Profile 188

Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma-Drug Profile 189

Small Molecules to Antagonize TRPV4 for Glaucoma-Drug Profile 190

Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology-Drug Profile 191

SNJ-1656-Drug Profile 192

SNJ-1945-Drug Profile 194

Stem Cell Therapy for Glaucoma-Drug Profile 195

Stem Cell Therapy for Glaucoma, Cerebral Palsy and Lupus-Drug Profile 196

Stem Cell Therapy for Macular Degeneration and Glaucoma-Drug Profile 197

Stem Cell Therapy for Ophthalmic Disorders-Drug Profile 198

SYL-040012-Drug Profile 199

Synthetic Peptide for Glaucoma-Drug Profile 201

tafluprost-Drug Profile 202

trabodenoson-Drug Profile 204

travoprost SR-Drug Profile 205

TRV-32R-Drug Profile 206

XY-0811QF2-Drug Profile 207

XY-1303LT2-Drug Profile 208

Glaucoma-Recent Pipeline Updates 209

Glaucoma-Dormant Projects 230

Glaucoma-Discontinued Products 232

Glaucoma-Product Development Milestones 233

Featured News & Press Releases 233

Appendix 242

Methodology 242

Coverage 242

Secondary Research 242

Primary Research 242

Expert Panel Validation 242

Contact Us 243

Disclaimer 243

List of Tables

Number of Products under Development for Glaucoma, H1 2015 19

Number of Products under Development for Glaucoma-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Comparative Analysis by Unknown Stage Development, H1 2015 29

Products under Development by Companies, H1 2015 30

Products under Development by Companies, H1 2015 (Contd..1) 31

Products under Development by Companies, H1 2015 (Contd..2) 32

Products under Development by Companies, H1 2015 (Contd..3) 33

Products under Development by Companies, H1 2015 (Contd..4) 34

Products under Development by Companies, H1 2015 (Contd..5) 35

Products under Investigation by Universities/Institutes, H1 2015 36

Glaucoma-Pipeline by AC Immune SA, H1 2015 37

Glaucoma-Pipeline by Acadia Pharmaceuticals Inc., H1 2015 38

Glaucoma-Pipeline by Aerie Pharmaceuticals, Inc., H1 2015 39

Glaucoma-Pipeline by Alcon, Inc., H1 2015 40

Glaucoma-Pipeline by Allergan, Inc., H1 2015 41

Glaucoma-Pipeline by Altacor Ltd., H1 2015 42

Glaucoma-Pipeline by Amakem NV, H1 2015 43

Glaucoma-Pipeline by Asahi Kasei Pharma Corp., H1 2015 44

Glaucoma-Pipeline by AUS Bio Limited, H1 2015 45

Glaucoma-Pipeline by Bausch & Lomb Incorporated, H1 2015 46

Glaucoma-Pipeline by Bionure Farma, S.L., H1 2015 47

Glaucoma-Pipeline by Can-Fite BioPharma Ltd., H1 2015 48

Glaucoma-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 49

Glaucoma-Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2015 50

Glaucoma-Pipeline by D. Western Therapeutics Institute, Inc., H1 2015 51

Glaucoma-Pipeline by DNAVEC Corporation, H1 2015 52

Glaucoma-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 53

Glaucoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 54

Glaucoma-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 55

Glaucoma-Pipeline by Gene Signal International SA, H1 2015 56

Glaucoma-Pipeline by Gilead Sciences, Inc., H1 2015 57

Glaucoma-Pipeline by Handok Inc., H1 2015 58

Glaucoma-Pipeline by High Point Pharmaceuticals, LLC, H1 2015 59

Glaucoma-Pipeline by Icon Bioscience, Inc., H1 2015 60

Glaucoma-Pipeline by IMMD Inc., H1 2015 61

Glaucoma-Pipeline by Inotek Pharmaceuticals Corporation, H1 2015 62

Glaucoma-Pipeline by InSite Vision Incorporated, H1 2015 63

Glaucoma-Pipeline by Lacer, S.A., H1 2015 64

Glaucoma-Pipeline by Merck & Co., Inc., H1 2015 65

Glaucoma-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 66

Glaucoma-Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015 67

Glaucoma-Pipeline by NeoStem, Inc., H1 2015 68

Glaucoma-Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 69

Glaucoma-Pipeline by NicOx S.A., H1 2015 70

Glaucoma-Pipeline by Ocata Therapeutics, Inc., H1 2015 71

Glaucoma-Pipeline by Ocular Therapeutix, Inc., H1 2015 72

Glaucoma-Pipeline by Ohr Pharmaceutical Inc., H1 2015 73

Glaucoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 74

Glaucoma-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 75

Glaucoma-Pipeline by Oxford BioMedica plc, H1 2015 76

Glaucoma-Pipeline by PharmaNova Inc., H1 2015 77

Glaucoma-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 78

Glaucoma-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 79

Glaucoma-Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015 80

Glaucoma-Pipeline by SIFI S.p.A, H1 2015 81

Glaucoma-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 82

Glaucoma-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 83

Glaucoma-Pipeline by Sylentis S.A., H1 2015 84

Glaucoma-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 85

Glaucoma-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 86

Assessment by Monotherapy Products, H1 2015 87

Assessment by Combination Products, H1 2015 88

Number of Products by Stage and Target, H1 2015 90

Number of Products by Stage and Mechanism of Action, H1 2015 94

Number of Products by Stage and Route of Administration, H1 2015 98

Number of Products by Stage and Molecule Type, H1 2015 100

Glaucoma Therapeutics-Recent Pipeline Updates, H1 2015 216

Glaucoma-Dormant Projects, H1 2015 237

Glaucoma-Discontinued Products, H1 2015 239

List of Figures

Number of Products under Development for Glaucoma, H1 2015 19

Number of Products under Development for Glaucoma-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 87

Assessment by Combination Products, H1 2015 88

Number of Products by Top 10 Targets, H1 2015 89

Number of Products by Stage and Top 10 Targets, H1 2015 89

Number of Products by Top 10 Mechanism of Actions, H1 2015 93

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 93

Number of Products by Top 10 Routes of Administration, H1 2015 97

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 98

Number of Products by Top 10 Molecule Types, H1 2015 99

Number of Products by Stage and Top 10 Molecule Types, H1 2015 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AC Immune SA

Acadia Pharmaceuticals Inc.

Aerie Pharmaceuticals, Inc.

Alcon, Inc.

Allergan, Inc.

Altacor Ltd.

Amakem NV

Asahi Kasei Pharma Corp.

AUS Bio Limited

Bausch & Lomb Incorporated

Bionure Farma, S.L.

Can-Fite BioPharma Ltd.

Cellular Biomedicine Group, Inc.

China Grand Wuhan General Pharmaceutical Research Institute

D. Western Therapeutics Institute, Inc.

DNAVEC Corporation

Dompe Farmaceutici S.p.A.

F. Hoffmann-La Roche Ltd.

Foamix Pharmaceuticals Ltd.

Gene Signal International SA

Gilead Sciences, Inc.

Handok Inc.

High Point Pharmaceuticals, LLC

Icon Bioscience, Inc.

IMMD Inc.

Inotek Pharmaceuticals Corporation

InSite Vision Incorporated

Lacer, S.A.

Merck & Co., Inc.

Merz Pharma GmbH & Co. KgaA

Mimetogen Pharmaceuticals Inc.

NeoStem, Inc.

Neurotech Pharmaceuticals, Inc.

NicOx S.A.

Ocata Therapeutics, Inc.

Ocular Therapeutix, Inc.

Ohr Pharmaceutical Inc.

Ono Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Oxford BioMedica plc

PharmaNova Inc.

Quark Pharmaceuticals, Inc.

Santen Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd.

SIFI S.p.A

SK Biopharmaceuticals Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Sylentis S.A.

Teva Pharmaceutical Industries Limited

Upsher-Smith Laboratories, Inc.

Glaucoma Therapeutic Products under Development, Key Players in Glaucoma Therapeutics, Glaucoma Pipeline Overview, Glaucoma Pipeline, Glaucoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com